Good morning. My name is Rob, I will be your conference operator today. At this time, I would like to welcome everyone to The Chemours Company fourth quarter and full year 2022 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by one on your telephone keypad. If you would like to withdraw your question, again, press the star one. Thank you. Jonathan Lock, Senior Vice President and Chief Development Officer, you may begin your conference. Hi, good morning, everybody, welcome to The Chemours Company's 4th quarter and full year 2022 earnings conference call. I'm joined today by Mark Newman, President and Chief Executive Officer, and Sameer Ralhan, Senior Vice President and Chief Financial Officer. Before we start, I'd like to remind you that comments made on this call, as well as in the supplemental information provided in our presentation and on our website, contain forward-looking statements that involve risks and uncertainties as described in Chemours' SEC filings. These forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events that may not be realized. Actual results may differ. Chemours undertakes no duty to update any forward-looking statements as a result of future developments or new information. During the course of this call, management will refer to certain non-GAAP financial measures that we believe are useful to investors evaluating the company's performance. A reconciliation of non-GAAP terms and adjustments are included in our release and at the end of our presentation. As a reminder, our prepared remarks, a full transcript, and an audio recording, plus our earnings deck, have been posted to our website alongside our earnings release. This morning's call will focus purely on Q&A. With that, I'll turn the call over to our CEO, Mark Newman. Mark? Thank you, Jonathan, and thank you all for joining us this morning. I'd like to start this morning by 1st thanking our Chemours employees, the entire 6,600 strong team Chemours for another great year. A year of improved results in revenue and earnings and high free cash flow conversion. A year in which we set several records, especially as we think of our TSS and APM businesses. As you saw in the results we posted last night, we had a difficult 4th quarter, and the results in the quarter were driven primarily by rising raw material costs, also with higher energy and logistics costs, which were further compounded by weaker-than-expected demand, mainly in our TT segment, which also feeds into our unit rate costs in the quarter. Clearly, the strong U.S. dollar and the winter storm at the very end didn't help, but clearly it was a weaker quarter. With that, you know, we have stepped back, and we looked at the year. We had a great year. With that in mind, you know, as we look at how we set the 2023 guide, I'd like to make a few comments. Our guide, in my mind, reflects our confidence in the work that's already on the way in TT to improve margins from where we left off in Q4 throughout the year to deliver margins that will be essentially in line with fiscal year 2022. We have a great foundation with TSS, and we're adding to that work that we're doing on input costs and plant efficiency. In TSS, the growth thesis is intact, you know, with mid to high single-digit top-line growth and comfort in getting back to greater than 30% margins for the full year, based on mix and volumes, and especially as we bear in mind the step down in quotas starting in early 2024. In APM, the growth thesis in our advanced electronics and clean energy applications, which provide very high value end use, is also intact. From a bottom-line perspective, clearly there will be some fade on less strategic businesses. Clearly, that will be impacted depending on the strength of global macro. And also, you know, our sense that we are very much involved in driving growth and investing in growth in our APM business, which has an impact on the margins. Nevertheless, with all these ingredients, we're confident in delivering margins, again, consistent with last year in the low 20s. Then finally, you know, the team continues to work on a number of legacy issues, both on legal and environmental areas, as we continue to resolve legacy issues. With that, we expect higher corporate and other spend in the year. Overall, we're starting the year on a weaker note with a lot of global macro uncertainty, but the team's very focused on all of these points in delivering another good year for Chemours in 2023. With that, Rob, I'll turn it over to you to open up for Q&A. At this time, I would like to remind everyone in order to ask a question, press star, then the number one on your telephone keypad. Your 1st question comes from the line of Duffy Fischer from Goldman Sachs. Your line is open. Yes, good morning. First question just around TiO₂. If you contemplate kinda your midpoint and, you know, the revenue guidance that you give. Can I read into that that's roughly or mostly, I guess, volume down and then maybe price off 1% or 2% with a little bit of relief on the raw material side? Is that the right way to think about what the mid-case feels like rolling through? Duffy, I think that, yes, a very good characterization. The way we're thinking of the year is, you know, a modest volume recovery in the 2nd half, but overall that would translate to volumes being down. Clearly, you know, TSS is working from a price perspective, and the team's hard at work on the input cost side and efficiency. Maybe I'll ask Sameer to comment further on some of the work we're doing on the cost side. Thanks, Mark. Duffy, as you're gonna look at the cost, definitely we've started seeing some of the relief on that side. As we kind of move through the year, we should start seeing the benefit of that. I would just caution a little bit as we kind of move into Q1, we are carrying a little bit of inventory, as you know, from the Q4 into Q1. As you kind of move through the year, the input cost relief should help us on the margin side. Fair enough. Then if you look back, you've had some good years in TiO₂, you know, kind of, let's say $3.25 billion or better on EBITDA. What does it take for this business to get back to that level, maybe over the next one to two to three years? Yeah, you know, great question, Duffy. Ed and his team are really energized around, you know, getting this business over time, you know, back to sort of a mid-20s EBITDA target margin. What it will take is full of plant utilization. Clearly, you know, volumes are down overall as we look at 2023 today. We expect, you know, that will continue to improve as we go into 2024. Clearly the team's quite focused on the cost side of the equation. Candidly, where we might be able to also deploy capital in that regard. A lot of work ahead of us, but, you know, I think where our view is this is a business, this is the best TiO₂ franchise, and, you know, we have a path to get here. Great. Thank you, guys. Thank you. Your next question comes from the line of Arun Viswanathan from RBC Capital Markets. Your line is open. Great. Thanks for taking my question. Yeah, I just, I guess I wanted to go back to a similar topic. You, you addressed some of the improvement in TiO₂. I guess on the TSS and APM side, I understand that the 2024 outlook definitely would get you back to that high single-digit growth. But in 2023, I know you faced tough comps in the 1st half, especially given the pricing that you realized last year, you know, double-digit gains in both businesses. We're also hearing some weakness on the electronics value chain as it pertains to APM. Could you just help us flush out how those two businesses kind of evolve through the year? You know, would you expect that those two businesses kinda grow in line with your targets in 2023 on an EBITDA basis? How should we think about that? Thanks. No, we certainly expect, as I said at the opening, continued growth in line with our long-term forecast on TSS in 2023. Clearly, you know, we are continuing to see growth in the deployment of our low global warming Opteon refrigerants as more and more stationary OEM players, you know, move to Opteon blend. You know, really good growth there. We are expecting growth in auto OEMs this year consistent with the IHS outlook. You know, a big part of the TSS business is aftermarket, you know, the replacement market in the stationary business and a growing pool of vehicles that require HFO technology. So let me just say, you know, we're seeing good demand signals here. Clearly, you know, with the quota now in place, this is the 2nd year, we don't expect the same kind of price delta as we saw going into last year. Certainly market dynamics continue to be very favorable with a effective quota regime. On APM, you know, we remain sold out on a number of product lines. We're sold out on Teflon PFA. Yeah, while there is some weakness in the electronics market, you know, new semicon fabs, especially where a U.S. supply chain is favored, you know, are moving forward. On our hydrogen economy business, there's a huge backlog on electrolyzers and PEM membranes required for those electrolyzers. You know, Denise and her team, while we're seeing some fade in less strategic products are really working at opening up capacity to meet customer demand in some of our higher value applications, you know, which we're investing in also, with some of the investments we announced last year. Overall, I think we're quite confident in the growth thesis of both TSS and APM. Okay. Thanks for that, Mark. Just as a quick follow-up, a couple years ago, you had mentioned about $125 million annual headwind from illegal imports of refrigerants into Europe from China. Is that still the range of what you're seeing? Is that also less imports into there? Would that also be a tailwind that you'd experience in TSS? Thanks. Yeah. You know, I think, we would say that the situation in Europe has improved. We continue to do a lot of work as an industry to monitor, illegal imports. My sense is, you know, as we're moving more and more to Opteon blends in the European e-equipment base, that's becoming less of a factor on its own. Sameer, I don't know if you have any other thoughts. No, I think Mark laid it out pretty nicely. Ernest, you kinda look at the guide and the impact that you laid out. Our guide, of course, anticipates that there's no further deterioration in any of the illegal import situation that we've seen in the past. At the same time, we're really excited about the growth that's coming from the U.S. side, right? With the AIM Act, and there's a much better regulatory regime, much better enforcement regime around these products, so that we feel very good about that. And the team is really focused on really pricing the products based on value-based strategy here. We feel really good about TSS business. Thanks. Your next question comes from the line of John McNulty from BMO Capital Markets. Your line is open. Yeah, good morning. Thanks for taking my question. On TSS, you know, it had a kind of wild ride in 2022, with some huge numbers in the, you know, 1st three quarters and then 4th quarter. I mean, look, you guys warned, "Hey, raw materials are gonna pinch us at some point." Certainly seemed to nick you a good bit more than I think we were expecting it to. I guess, can you help unpack that? I guess, you know, with your optimism for hitting 30% plus in 2023 in terms of the margins, you're kinda going back to your normal-ish levels. I guess, how should we think about the cadence of the recovery there? Maybe, you know, maybe even a little bit of color for 1 Q would be helpful. Yeah. John, let me start, and then I'll ask Sameer to give you some added color on sort of the Q4 margins and some of the mechanics and calculus behind the numbers. Let me start by saying, you know, we are fully. Let me start by saying Q4 in TSS was weaker than we expected. While we were projecting lower margins in the quarter, we were disappointed with our own results in the quarter. Sameer will take you through, you know, how the math works. As it relates to 2023, Q4 and the unique attributes of Q4 should not be viewed as any way as overshadowing the year we expect ahead of us in 2023. While we don't give a quarterly guide on our-- on any of our segments, we would expect our recovery, our margin recovery to start early in the year. As I said, we expect our full year margins to be north of 30% consistent with our long-term guide. Maybe I'll ask Sameer, to give us some more color on Q4. Thanks. Thanks, Mark. As we look at the Q4 margin, right, on the TSS side, it's really driven by three factors. First one is really what you would expect with a typical seasonality in the business, because in the 4th quarter, our product mix tends to be more Southern Hemisphere based. These are lower margin products for us. From a seasonality perspective, the Q4 margin generally are gonna be a little lower than the 2nd and 3rd quarter. The other two factors were really kind of specific to the timing at this point. 1st one is the raw material inflation that hit us in, as some of the products coming that we are exporting, kind of their prices increased. The other one was a lower fixed cost absorption, which happened because of the plant turnarounds in the early part of the quarter. In December, the winter storm had a pretty meaningful impact on the business as well at Corpus. Those two driving the unit rates, and given that we are a LIFO company, we took a lot of that cost up front in this quarter. As we gotta go into Q1 and into 2023, the margin should moderate back towards the guidance that we have given for the longer-term margin of the business. Okay. That's helpful color. On the APM business, you know, for the 1st time, you're kind of breaking it out now into two new segments. I guess, can you help us to understand the margin profile roughly? I mean, obviously, you didn't give it, so maybe you don't want explicit detail out there. How should we think about maybe the difference in the margins between them, considering one is higher growth and seems like certainly higher value, but you're also investing a lot in it, and one maybe is a little bit, you know, taking less investment, but also may be a little bit less value add. I guess, can you help us to think about the margin differential there? Yeah. I'd say our entire APM portfolio has very good or very high variable margin. Clearly value and use on something, you know, like a PEM membrane in an electrolyzer or a very high purity PFA for, you know, small node semicon applications, fabs, you know, carry a premium to the portfolio on average. I think the intent of breaking out our performance solutions versus our advanced materials was really to demonstrate the growth rate over time. Clearly, the numbers in the chart, you know, using, you know, three years of financials start with a COVID year. You know, the growth rates are probably a little higher on our advanced materials than we would expect over time. Recall that we expected growth in our performance solutions to really start to accelerate as we approach the middle of the decade. We felt it was important for investors to reflect that double-digit growth rate, which is a, you know, a multiple of GDP, as we move forward. Clearly, you know, we view that as a premium business, both in terms of a strategic value and obviously margin, to the rest of the portfolio. Got it. Thanks very much for the call. I I appreciate it. Your next question comes from a line of Matthew DeYoe from Bank of America. Your line is open. Morning. Can you talk through just the working capital headwinds to cash flow, thinking primarily inventories? How will that balance out? Is that gonna drive lower operating leverage in 1Q? I guess what should we think for working capital headwinds, tailwinds for the year? Yeah, Matt, why don't I take this one and Mark can comment afterwards. Essentially, as we kind of look at the working capital, really it's predominantly in the TT business that you've seen in Q4. As we kind of move into 2023 into Q1 and beyond. Q1, as you know, seasonally, we typically consume working capital, right? Because of the seasonality both of the TT business and the TSS business. We will consume working capital in Q1, but as we kind of move through the year, we should be able to release that working capital. That's reflected in the guide that we've given for the free cash flow greater than $350 million. Okay. I want to talk about PFAS. There's a potential or proposed ban in Europe, and wondering what that looks like for your thoughts on the Nafion expansion in France. I guess conversely, you know, 3M announced that it was closing some of its PFAS or all of its PFAS operations. I mean, what are you thinking about or how are you thinking about that as an opportunity for your business and potential market share gains over the next years? Maybe I'll start with the 3M 1st. Clearly, the way we think about it, you know, fluorine chemistries are essential, and we believe, based on our technology, can be made responsibly. We, we continue to make significant investments in driving that growth, whether it's, you know, for semicon applications, especially as countries around the world look at, you know, shoring up their own semicon supply chain or, you know, whether it's, you know, in hydrogen, you know, renewable hydrogen, you know, where we're really focused or, candidly also in the EV applications, where our polymers are critical. If you want these technologies, you know, our view today is, you know, fluoropolymers are the best solutions for those needs. Clearly, you know, 3M made a decision based on what they thought was prudent for them and their shareholders. We think it's prudent to continue investing in making fluoropolymers responsibly for the next generation of the economy. As we think about the dossier in Europe, clearly that's a multi-year process. We will be very engaged working with our customers, working with the same industries that I just talked to, you know, make it very clear to regulatory authorities that this is a chemistry that Europe should embrace, and they should embrace participants like ourselves who can make this chemistry responsibly. We have always been an advocate of science-based regulations, and in fact, you know, we have science-based targets in our scope one, two, and three emissions. you know, this is the beginning of a long journey as it relates to the dossier, but you can expect that we will be very involved and very vocal with our customers in why we believe fluorine chemistry has a place in modern society. Understood. Thanks. Your next question comes from a line of Josh Spector from UBS. Your line is open. Yeah. Hey, thanks for taking my question. Wanted to see if I could try again on the cadence of earnings through the year. I mean, getting a lot of questions from investors about really for 1st quarter and what that step-ups looks like. Is there any way you can frame kind of a range of what you're assuming there or maybe 1st half, 2nd half? You know, relatedly, when you look at your range for the year, the low end, you talked about recessionary conditions. What really plays out in that scenario? I guess how conservative is that relative to what you're seeing today? Thanks. Yeah. Josh, thanks for your question. Clearly the team's really focused coming off of Q4, you know, to drive improved results, you know, starting in Q1. Let me just say the team's fully energized around delivering a great year, and we need to make every quarter count. You know, as I think about the. You know, as Sameer alluded to, there were some cost issues in Q4. That were unique to Q4. Clearly, you know, we've started to see on some of the input costs, some rollover, you know, starting already. Clearly we're seeing, you know, if you're looking at nat gas prices in the U.S., which really impacts our TT operations, you're seeing big improvement there. You're seeing a weaker U.S. dollar, which is also helpful. I would say that there were some unique cost issues in Q4, which won't, you know, we would not expect to repeat in Q1. On the demand side, clearly, you know, TT is gonna start off the year in a weaker place. We expect, you know, some moderation based on, you know, the end of destocking in Europe, the improvement in Asia after the, you know, Lunar New Year. You know, we're continuing to see the U.S. hang in there as we move through the year. As we said earlier, you know, our TSS franchise is very strong, and so we would expect to see a good start to the year starting in Q1. On APM, yes, we have the higher costs on some of the input costs flowing through, which really impacted Q4. Also we see in the year the ramp-up of growth by relieving capacity constraints in some of our higher value applications. Listen, I think it'll be a journey throughout the year, but clearly I wanna make it clear that we're very focused on making every quarter count. Maybe I'll ask Sameer to give a little more color. No, thank you, Mark. Josh, as you're gonna look at the three businesses, right? On the TT side, as you're gonna look through the year, as we said in the, in the prepared remarks and in the, in the investor deck as well, we anticipate the destocking to near to be near end. As we kinda think about the rest of the year, the demand recovery, the way we have modeled and what you see in the guide is really through the 2nd half of 2023. It's a very slow ramp that we have, we anticipate at this point. On the TSS side is, you know, only one thing additive I would say to what Mark's already said is, you know, given all the market and regulatory dynamics, we feel pretty good from the demand perspective. We still believe, you know, as you kinda look at the reopenings post-COVID, there's still a backlog on the commercial side. We anticipate to that to provide the tailwinds as we kinda get into the spring season and especially in the 1st half of the year. APM has lesser seasonality, but it'll be a, you know, the trend should be similar to this year. Okay, thanks. I mean, if you could just comment on the lower end of the guide, I guess what's baked in there in terms of recessionary expectations. Just, I guess, a follow-up to the prior one, could you size the cost benefit you expect to see sequentially? If you look at the low end side in the modest recession, what we have assumed is that U.S. will have a modest recession, and also the recovery in Europe and Asia will be delayed until 2024. That's the way we kinda model from an economic scenario point of view. Of the, our three businesses, as you know, TT is the most economically sensitive business, so that's a big part of the guide range. Your next question comes from the line of Hassan Ahmed from Alembic Global Advisors. Your line is open. Morning, Mark and Sameer. you know, I'm just taking a look at the guidance, for 2023, and specifically on the TT side of things. you know, you guys had adjusted EBITDA margins of 7% in Q4. If I take a look at the commentary you're giving or baking into 2023 guidance, you know, you're talking about 2023 adjusted EBITDA being similar to 2022, so, you know, call it around 18%. I'm just trying to understand how we bridge to that? Hassan, thanks for the question. Clearly, we would expect to see margin improvement in TT starting in Q1. as Sameer said, some of the higher cost inventory will still be flowing through the P&L. Already, you know, we're seeing, you know, some improvement in input costs that will start to impact our business in Q1. The guide, as Sameer said, the bottom and the top end of the range are really tied to how strong or weak the 2nd half recovery is with respect to TT volumes. I'd say for the full year, you know, we are expecting volumes to be down year-over-year slightly. The range of volume delta to 2022 will depend on the 2nd half recovery. Clearly, as we get better utilizations of our plants in the 2nd half and lower input costs, you know, we arrive back at a full year EBITDA margin in line with 2022. Hassan, Just one more thing I would say on the margin side, to what Mark just said is the margin recovery will be through the year. You're not see getting 18% right away, but this will be a margin recovery through the year. As the things that have started easing up on the cost side, thanks to the great work with the team and also on the commercial side, by Ed and team, those things should really start flowing and benefiting the P&L and the margin as we kinda go through the year. It'll be a modest improvement for the year. Understood. Very helpful. As a follow-up, you know, just sticking to the guidance. On the EPS side of things, I mean, I take a look at the EPS range for 2023 you guys have given, and it assumes a flat sort of shares outstanding, right? You guys obviously repurchased $144 million in shares in Q4, $495 million in 2022. I'm just trying to understand how we should think about sort of, you know, the run rate for buybacks and as it relates to the guidance as well. clearly we don't factor, you know. We keep the share count constant, as you noted, Hassan, in our guidance. clearly, you know, we have demonstrated historically, you know, our willingness to return cash to shareholders while also deleveraging and funding the escrow, if you saw how we deployed capital. As you think about this year, with our free cash flow guide of greater than $350 million, the way I think about capital allocation this year is we're stepping up our investment in growth, to fund, you know, really high return applications in both TSS and APM. clearly, you know, we think we're at a prudent leverage ratio today. But, you know, we will also keep in mind, and we have an approval from our Board around stock repurchases. Clearly, as we think of the year also, I would just say, you know, we're keen to resolve, you know, legacy claims against the company. We wanna also factor that in mind as we think of the five key strategic priorities which drive value for our shareholders over time. Listen, the point is well taken on the share count. We will continue to deploy capital against, you know, the four key priorities, the top four, but we'll also use capital allocation wisely to drive or augment the value from those 1st four priorities as we move forward in time. Very helpful. Thank you so much, guys. Thank you. Your next question comes from the line of Vincent Andrews from Morgan Stanley. Your line is open. Thank you very much. Could I just ask, you know, in your TiO₂ comments, you talk about the recovery through the year, and you spend a lot of time referencing Europe and Asia and China, which is easy to understand. Could you talk about sort of the end markets and, you know, I think we all have a pretty good idea of what's going on in paint and coatings, but what about the balance of the book? What are you seeing in terms of how those customers are behaving, and what is your expectation for how their volume is gonna flow through the year? Yeah. Well, clearly, as we think of our TiO₂ business globally, you know, the majority of our product ends up in architectural coatings. You know, the U.S. market continues to be robust. There is still, and if you listen to some of the calls by coating customers, a backlog on the professional side. Europe, you know, is a primarily a coatings market for us as well. We had seen, you know, pretty significant destocking in the 2nd half, especially in Q4. You know, we're seeing signs that that's moderating. China is a high-end coating market for us, also a laminate market. We're also big in laminates in Europe. Those markets are tied to end consumer demand in, you know, whether it's furniture or flooring or kitchen cabinets. You know, again, in Europe, I think the expectation is we'll start to see some return as the end consumer becomes less stressed, you know, as it relates to energy cost in Europe. Finally, you know, the last part of our business is in plastics. You know, that tends to be more tied to global macro, I would say generally. But even there, you know, I would say, you know, if we look at, you know, strong auto globally and other applications like that, we would expect, you know, continued recovery throughout the year as well off of, you know, what we saw in the 2nd half of last year. Okay. Just as a follow-up, I just wasn't 100% clear on TSS in the 4th quarter on the volume side of the equation, whether that came in below your expectations, and what caused it? Yeah. I'd say, TSS, you know, seasonally, Q4 is a weak quarter, right? As you know, you know, the season can either be relatively good or relatively weak. I would say, you know, our volumes were somewhat lower than expectation. I would say what transpired in Q4, which Sameer took us through in detail, is more some of the movements on the cost side. You know, it's seasonally a weak quarter. We had some pretty major plant turnarounds or TARS, as we call them, that, you know, were completed in Q4. You always have the startup from a major TAR. You know, you have a lot of costs being absorbed as you bring your plants up online. We had the winter storm, you know, at the end, which also resulted in either lower operating rates or, you know, higher costs related to how you remediate the plants after the storm. I'd say, you know, Q4 from a TSS perspective, had elements of maybe slightly weaker demand, but I would say the cost factors were probably more significant in terms of the margin compression that we saw. Thanks so much. Your next question comes from a line of John Roberts from Credit Suisse. Your line is open. Thank you. Could you comment on the backlog for Nafion? Do you think the backlog accelerates in 2023 after the IRA? How far out are you taking orders? John, that's a great question. You know, as I understand it, there was a 2-year backlog on PEM electrolyzers before IRA. With IRA, you know, the inbound requests for access to our capacity are significant. Denise and her team are really working hard to unlock existing capacity. Clearly, you know, we're involved in hydrogen in a very significant way. We have the announced joint venture with FUMATECH in Germany. We're a partner in the Hydrogen Hub application for West Virginia. We also announced the, you know, the partnership with the DOD on clean hydrogen at our facility here, you know, with the University of Delaware here in Delaware. A lot going on in the hydrogen space, and Chemours continues to be extremely relevant in the work we're doing, both on improving membranes, but also improving our volumes to meet the significant backlog in announced projects globally. You mentioned higher legal costs in 2023. Is that related to preparing for the 1st trial for PFAS or increased settlement negotiations or something else there? Yeah. you know, I'd say, you know, we've been in settlement discussions regarding the water utility cases and have now progressed those discussions through the court-appointed mediator. you know, in anticipation of the work we're doing there and other aspects, you know, we're also very focused there. Clearly, we have a number of major remediation projects too online that we're bringing to completion. maybe I'll ask Sameer to give some more granularity. I think Mark touched it, John. The way I would think about the guide on the corporate and other side, which I'm assuming you're referring to, it's a combination of both the legacy environmental and, some of the legal costs. It's not just legal. Good. Thank you. There are no further questions at this time. Mr. Mark Newman, I turn the call back over to you for some final closing remarks. Thanks, Rob. Again, we're really excited as we look into the new year at, you know, where we're going with Chemours in our next chapter. We're really excited about the work we're doing to drive improved results in TT and prosecuting the growth in TSS and APM and resolving some of the legacy issues that, you know, we've had since our inception. A lot of good work here being done. I look forward to seeing as many of you as possible this year and, you know, getting the word out on what Chemours is doing around sustainability-led growth going forward. Thank you, and look forward to seeing you all this year. This concludes today's conference call. Thank you for your participation. You may now disconnect.